‘It’s Total Charlatanism’: What We Heard This Week

— Quotable quotes heard by MedPage Today‘s reporters

by
MedPage Today Staff


July 2, 2023

“It’s total charlatanism.” — Thomas Albini, MD, of the University of Miami in Florida, discussing eye injuries from unproven stem cell treatments claiming to treat eye and neurological conditions.

“To see something like this in my lifetime is pretty impressive.” — Carel Le Roux, PhD, of University College Dublin in Ireland, on how investigational retatrutide induced the biggest weight loss yet recorded in an obesity trial.

“There is a non-small percentage of people who absolutely, really feel horrible on these medications.” — Jody Dushay, MD, of Beth Israel Deaconess Medical Center in Boston, explaining side effects of semaglutide (Ozempic/Wegovy).

“Why wouldn’t MS severity be affected by genetic factors?” — Gavin Giovannoni, MBBCh, PhD, of Queen Mary University of London in England, about the discovery of the first genetic variant associated with faster disease progression in multiple sclerosis.

“I have been doing cardiovascular trials for 30 years, and I can tell you we have never seen a hazard ratio as favorable as this.” — Steven Nissen, MD, of the Cleveland Clinic in Ohio, on the effect of bempedoic acid (Nexletol) cardiovascular events in high-risk, statin-intolerant patients.

“We’ve seen this before.” — David Sullivan Jr., MD, of the Johns Hopkins Malaria Research Institute in Baltimore, on locally acquired malaria cases reported in the U.S.

“If you look who is the closest friend of the gut, that’s the liver.” — Aleksander Krag, MD, PhD, MBA, of Odense University Hospital in Denmark, discussing fecal microbiota transplants in patients with cirrhosis.

“The average doctor is not really much affected by the changes that are hitting Twitter.” — Greg Matthews, CEO of HealthQuant, on physicians using Twitter after Elon Musk purchased the platform.

“So far, it’s nothing that we’ve seen to [be the] cause for concern or alarm.” — Kelly Oakeson, PhD, of the Utah Department of Health and Human Services, on the newest COVID variants hitting the U.S.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Etoposide Plus Trastuzumab Shows Benefit in Metastatic BCa thumbnail

Etoposide Plus Trastuzumab Shows Benefit in Metastatic BCa

The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway In heavily pretreated women with HER2-positive metastatic breast cancer (MBC), the combination of etoposide and trastuzumab yielded prolonged responses in some patients, with manageable toxicity. Why This Matters The clinical benefit of the…
Read More
Thanks to COVID-19, Drug Shortages Take Center Stage thumbnail

Thanks to COVID-19, Drug Shortages Take Center Stage

When a patient's cardiac arrest triggers a Code Blue, clinicians respond with swift precision — until they have to hit a brief pause. Instead of a prefilled syringe or 1 mL premixed vial of life-saving epinephrine in the code cart, there's a vial of concentrated epinephrine, a sodium chloride solution for dilution, a syringe, and…
Read More
Train traffic between St. Gallen and Zurich impaired thumbnail

Train traffic between St. Gallen and Zurich impaired

Die SBB-Strecke zwischen St. Gallen und Gossau ist wieder in Betrieb. Die Störung ist behoben. Reisende müssen aber noch mit Verspätungen rechnen. Derzeit fahren keine Schnellzüge von St. Gallen auf der Normalroute über Winterthur nach Zürich. Gian Ehrenzeller / KeystoneDie für Pendler wichtige SBB-Verbindung zwischen St. Gallen und Zürich ist am Freitagmorgen schwer beeinträchtigt gewesen.…
Read More
Index Of News
Total
0
Share